cbdMD, Inc. (YCBD) · Nov 4, 2026 · Acquisition

cbdMD acquisition closes Twinlab deal, but debt and dilution rise

Twinlab acquisition closed — $1.75M assumed debt; 2.23M shares issued at $1.00

cbdMD’s acquisition of Twinlab has closed, expanding its supplement portfolio beyond hemp—but adding debt, dilution and integration risk.

cbdMD is a small, growing wellness company trying to reduce its exposure to hemp-derived products while regulatory uncertainty threatens part of that business. Its latest reported quarter showed 20% year-over-year revenue growth, but 64% of quarterly revenue came from products potentially affected by THC-limit changes; management had already identified channel and portfolio diversification as a strategic response.

The diversification plan is now operational, not just announced. cbdMD completed the previously disclosed purchase of Twinlab’s operating assets and brands, including Twinlab, Reserveage, Metabolife and ResVitale, adding vitamins, sports nutrition, weight management and longevity products across retail, wholesale and direct-to-consumer channels. The transaction was already public since September 2, so the closing itself is partly known rather than a surprise; the meaningful change is that cbdMD now owns the assets and must execute the integration. The earlier announcement targeted roughly $30 million of combined trailing revenue, versus cbdMD’s roughly $20.9 million trailing revenue before the deal, implying a material increase in scale if the acquired revenue is retained.

The strategic benefit comes with real balance-sheet and ownership costs. cbdMD assumed $1.75 million of senior secured debt at 9% interest, due in two years, secured by the acquired assets. 〔0〕 It also issued 2,229,805 shares to the secured creditor at $1.00 per share, equal to 19.9% of outstanding shares at signing, with another 132,730 shares contemplated subject to shareholder approval.

The filing establishes the asset base but not yet the earnings quality. cbdMD says the acquired brands had received limited marketing investment and expects its internal team to revive them, but the filing provides no acquired income statement, cash-flow data or pro forma profitability. The required historical and pro forma financial statements are deferred to a later amendment, leaving the market without a clean view of Twinlab’s current revenue, margins or working-capital needs.

Bottom line: Closing Twinlab meaningfully advances cbdMD’s move beyond hemp and could roughly expand its revenue base, but the filing is not yet proof that the acquired brands are profitable or that the integration will work. It is a modestly positive strategic step, paid for with debt, dilution and execution risk.

What to watch next

Amended filing with Twinlab financials and pro forma results

Original filing on SEC EDGAR